21 2月 2018 by admin in UncategorizedComments Centrexion Therapeutics Announces First Patient Dosed in Phase 3 Trial of CNTX-4975 for the Treatment of Moderate to Severe Knee Osteoarthritis Pain
07 2月 2018 by admin in UncategorizedComments Syros Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
30 1月 2018 by admin in UncategorizedComments resTORbio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
25 1月 2018 by admin in UncategorizedComments ARMO BioSciences Announces Pricing of Initial Public Offering
16 1月 2018 by admin in UncategorizedComments Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Knee Osteoarthritis Pain
03 1月 2018 by admin in UncategorizedComments Crescendo Biologics announces Humabody® evaluation in CAR-T by Takeda
